Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosuvastatin is a statin (HMG-CoA reductase inhibitor) used to lower cholesterol and triglycerides in the blood, reduce the risk of heart attack and stroke, and treat familial hypercholesterolemia. It works by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production and increased hepatic uptake of LDL[1][2][5][6][8]. BCX7353 is a synthetic small molecule oral plasma kallikrein inhibitor developed for hereditary angioedema (HAE). It inhibits plasma kallikrein within the kallikrein-kinin system to prevent bradykinin-mediated swelling attacks. BCX7353 is taken orally for both acute treatment and prophylaxis of HAE[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rosuvastatin + BCX7353.